LungLife AI (Cynvenio) Names Sara Barrington as Chief Executive Officer
WESTLAKE VILLAGE, CA – January 2, 2019 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that its Board of Directors has named Sara Barrington as Chief Executive Officer and Board member.
Ms. Barrington has more than 20 years of executive leadership experience with focus in biotech. Before joining LungLife AI, she served as part of the Executive Team at Bruin Biometrics, an LA-based medical device company and prior to that at Exosome Diagnostics, a venture-backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer. Previously, she served as CFO for Creative Technology Group, Inc and AusAm Biotechnologies developing novel early stage kidney disease diagnostics.
“The Board is pleased to welcome Sara and we strongly believe that she is the right leader to take LungLife AI into its next stage of development,” said Simon Raab, Executive Chairman of LungLife AI’s Board of Directors. “The company’s diagnostic solutions are poised to transform the diagnosis and management of lung cancer and Sara’s experience in both strategy and strategic execution for emerging life science companies make her the right candidate to successfully lead LungLife AI to market.”
“LungLife AI has been a pioneer in the development of liquid biopsy testing technology and molecular analysis,” commented Sara Barrington. “I look forward to working with the talented LungLife AI team to build upon the company’s progress and to bring these important solutions to physicians and cancer patients worldwide.”
About LungLife AI, Inc.
LungLife AI is focused on the development of cancer diagnostic solutions, particularly in lung disease, recognizing the need to substantially improve patient outcomes. The company’s tests span all stages of cancer and are designed to deliver actionable information to clinicians via minimally invasive blood draw. LungLife AI is based in Thousand Oaks, California. For more information, please visit https://www.lunglifeAI.com/.
LiquidBiopsy® is a registered trademark of LungLife AI, Inc.